Literature DB >> 8630392

Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane.

G Ramaschi1, M Torti, E T Festetics, F Sinigaglia, F Malavasi, C Balduini.   

Abstract

CD38 is a cell surface molecule widely used as a marker for immature and activated lymphocytes. It has been recently shown that CD38 displays three enzymatic activities: hydrolysis of NAD+ to ADP-ribose, synthesis of cyclic ADP-ribose from NAD+, and hydrolysis of cyclic ADP-ribose to ADP-ribose. Thus, CD38 plays a key role in the synthesis of cyclic ADP-ribose, a calcium-mobilizing compound. We investigate here the expression and cellular localization of CD38 in human platelets using a specific monoclonal antibody. Results showed that CD38 is expressed by human platelet membranes. Moreover, we show that platelet CD38 possesses NAD glycohydrolase, ADP-ribose cyclase, and cyclic ADP-ribose hydrolase activities. This finding indicates that the calcium-mobilizing agent cyclic ADP-ribose can be synthetized by human platelets and raises the question about the possible role of CD38 expression and enzymatic activities in the signal transduction pathways leading to platelet activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630392

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

2.  Critical role for CD38-mediated Ca2+ signaling in thrombin-induced procoagulant activity of mouse platelets and hemostasis.

Authors:  Mazhar Mushtaq; Tae-Sik Nam; Uh-Hyun Kim
Journal:  J Biol Chem       Date:  2011-02-21       Impact factor: 5.157

3.  cADP-ribose formation by blood platelets is not responsible for intracellular calcium mobilization.

Authors:  P Ohlmann; C Leray; C Ravanat; A Hallia; D Cassel; J P Cazenave; C Gachet
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

Review 4.  Anti-CD38 autoantibodies in type? diabetes.

Authors:  Roberto Mallone; Paolo Cavallo Perin
Journal:  Diabetes Metab Res Rev       Date:  2006 Jul-Aug       Impact factor: 4.876

5.  Adenylic dinucleotides produced by CD38 are negative endogenous modulators of platelet aggregation.

Authors:  Mirko Magnone; Giovanna Basile; Debora Bruzzese; Lucrezia Guida; Maria Grazia Signorello; Madhu Parakkottil Chothi; Santina Bruzzone; Enrico Millo; Ai-Dong Qi; Robert A Nicholas; Matthias U Kassack; Giuliana Leoncini; Elena Zocchi
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

6.  NAD-dependent inhibition of the NAD-glycohydrolase activity in A549 cells.

Authors:  Enrico Balducci; Luigi G Micossi
Journal:  Mol Cell Biochem       Date:  2002-04       Impact factor: 3.396

Review 7.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 8.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

Review 9.  Anti CD38 monoclonal antibodies for multiple myeloma treatment.

Authors:  Alessandro Gozzetti; Sara Ciofini; Martina Simoncelli; Adele Santoni; Paola Pacelli; Donatella Raspadori; Monica Bocchia
Journal:  Hum Vaccin Immunother       Date:  2022-04-11       Impact factor: 4.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.